Sichenzia Ross Ference LLP Represents INmune Bio Inc. in an $8 Million Initial Public Offering and Listing on the Nasdaq Capital Market
Press Release – New York, NY – February 5, 2019 – Sichenzia Ross Ference (“SRF”), a leading securities and corporate law firm, is pleased to announce that the firm has represented INmune Bio Inc. (INMB), an immunotherapy company focused on developing therapies that harness the patient’s innate immune system to fight disease, in an initial public offering at a price of $8.00 per share resulting in gross proceeds of approximately $8,000,000 and listing on the Nasdaq Capital Market under the ticker symbol INMB.
The SRF team was led by Partners Marc Ross, Thomas Rose and David Manno. View more of Sichenzia Ross Ference’s IPO transactions, here.
.jpg)
Sichenzia Ross Ference LLP
Sichenzia Ross Ference LLP is a nationally recognized securities and corporate law firm that provides experienced representation in all matters involving the securities industry. Super Lawyers consistently recognizes our attorneys as among the highest rated securities lawyers in the nation. Our attorneys specialize in advising clients on private placements, initial (IPOs) and secondary public offerings, alternative public offerings, preparation of SEC filings and listings on major capital stock exchanges such as the NYSE (New York Stock Exchange), NASDAQ and OTC markets. In addition, our litigation and arbitration attorneys are highly skilled in representing clients from routine lawsuits to complex cases before the SEC, FINRA and other tribunals. We also represent clients in a range of residential and commercial real estate and trusts and estates matters.
Visit SRF's LinkedIn page
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Attorneys Selected for Inclusion on 2019 Super Lawyers Lists - October 16, 2019
- Sichenzia Ross Ference LLP to Join Client Relmada Therapeutics, Inc. at Nasdaq Opening Bell Ringing - October 15, 2019
- Sichenzia Ross Ference LLP Congratulates Relmada Therapeutics, Inc., on NASDAQ Uplisting - October 10, 2019
